Director / PDMR Dealing
Optima Health plc
Director / PDMR Dealing
Optima Health plc (Company) announces that on 23 September 2026, awards were granted under the Optima Health plc Performance Share Plan (PSP) to certain directors and PDMRs.
The Awards take the form of nil-cost options which vest on the second anniversary of grant, subject to certain conditions including continued employment with the group and the achievement of performance targets. 50% of the shares that vest are then subject to a further one year holding period before they can be exercised.
In addition, further to the information on the 2024 Share Plan set out in the Company’s Admission Document and the recent notice of Annual General Meeting, the Company confirms that awards under the 2024 share plan have been granted to a number of senior management/PDMRs. Subject to achievement of the performance hurdle, nil cost options would be granted to the relevant participants according to the plan rules.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation as incorporated into the law of England and Wales, and set out more details of the transactions.
|
1. |
Details of PDMR |
|||||
|
(a) |
Name |
1. Jonathan Thomas 2. Andy Bones 3. Joanne Newey
|
||||
|
2. |
Reason for notification |
|||||
|
(b) |
Position / status |
1. Chief Executive Officer 2. Chief Financial Officer 3. Chief Commercial Officer (PDMR)
|
||||
|
(c) |
Initial notification / amendment |
Initial notification |
||||
|
3. |
Details of the Issuer |
|||||
|
(a) |
Name |
Optima Health plc |
||||
|
(b) |
LEI |
213800TOPWJSRCW4ON08 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) have been conducted |
|||||
|
(a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares in the capital of Optima Health plc (Shares) GB00BRSCY602 |
||||
|
(b) |
Nature of the transaction |
Grant of an option under the PSP to acquire Shares at nil cost |
||||
|
(c) |
Price(s) and volume |
|
||||
|
(d) |
Aggregated information |
|
||||
|
(e) |
Date of the transaction |
23 September 2026 |
||||
|
(f) |
Place of the transaction |
Outside a trading venue |
||||
|
Name of PDMR |
Cumulative % of total value of 2024 Share Plan value (subject to performance hurdles) |
|
|
|
|
Jonathan Thomas |
50% |
|
Joanne Newey |
10% |
|
|
|
|
|
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE